1. Home
  2. SRL vs ADAG Comparison

SRL vs ADAG Comparison

Compare SRL & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scully Royalty Ltd.

SRL

Scully Royalty Ltd.

HOLD

Current Price

$6.13

Market Cap

96.5M

ML Signal

HOLD

Logo Adagene Inc.

ADAG

Adagene Inc.

N/A

Current Price

$3.88

Market Cap

254.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SRL
ADAG
Founded
2017
2011
Country
China
China
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
96.5M
254.4M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
SRL
ADAG
Price
$6.13
$3.88
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.25
AVG Volume (30 Days)
12.8K
95.1K
Earning Date
05-12-2026
04-01-2026
Dividend Yield
16.07%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.13
$1.44
52 Week High
$10.39
$4.75

Technical Indicators

Market Signals
Indicator
SRL
ADAG
Relative Strength Index (RSI) 28.74 50.91
Support Level $5.37 $3.35
Resistance Level $6.44 $3.99
Average True Range (ATR) 0.35 0.32
MACD -0.02 0.01
Stochastic Oscillator 48.57 66.46

Price Performance

Historical Comparison
SRL
ADAG

About SRL Scully Royalty Ltd.

Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: